Oncology - European Medical Journal

Continue

Oncology

Filter
3 Mins
9 Aug 2017

Spasmodic Dysphonia: What About It?

Spasmodic dysphonia (SD): what about it? That is the million-dollar question.
13 Dec 2016

Recent Developments in Regorafenib Treatment for Gastrointestinal Cancers: Presentations at the Meeting of the European Society for Medical Oncology (ESMO) Congress 2016

The European Society for Medical Oncology (ESMO) Congress was held in Copenhagen, Denmark from 7th–11th October 2016. The use of the promiscuous…
9 Mins
22 Nov 2016

State-of-the-Art Integration of Multiple Kinase Inhibitors in the Treatment of Gastrointestinal Cancers

This symposium provided an overview of the efficacy and safety of multikinase inhibitors in colorectal cancer, including treatment sequencing, followed…
10 Mins
22 Nov 2016

Optimising Salvage Therapy in Aggressive B Cell Non-Hodgkin Lymphoma

Prof D’Amore opened the symposium by highlighting that management of patients with relapsed or refractory aggressive B cell non-Hodgkin lymphoma…
2 Mins
22 Nov 2016

Cabozantinib as First-Line Therapy for Patients with Metastatic Renal Cell Carcinoma with Poor or Intermediate-Risk Characteristics

The oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) sunitinib is a standard first-line therapy for patients with…
8 Mins
22 Nov 2016

Regorafenib in Metastatic Colorectal Cancer and Advanced Soft Tissue Sarcomas

Oncologists face multiple challenges when treating patients with cancer, especially if patients are elderly or if they experience adverse events (AEs).
8 Mins
22 Nov 2016

Editor’s Pick: Muscle Dysfunction in Childhood Cancer: Biological Mechanisms and Implications for Long-Term Survivorship

Paediatric cancer treatment has advanced significantly over the last half century to a point where >80% of all childhood cancer cases survive >5 years…
8 Mins
22 Nov 2016

The Importance of Mutational Analysis in Chronic Myeloid Leukaemia for Treatment Choice

Since their introduction in 2001, tyrosine kinase inhibitors (TKIs) targeting BCR-ABL have become the standard therapy for chronic myeloid leukaemia (CML).
We’ve noticed you’re accessing
from North/South America.